JPMorgan analyst Brian Cheng raised the firm’s price target on PTC Therapeutics (PTCT) to $89 from $80 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q1 report. PTC has confidence in Sephience’s growth in the U.S., noting that uptake in March was strong, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics’ Earnings Call Highlights Sephience Surge
- Trump plans to fire FDA commissioner Marty Makary, WSJ reports
- PTC Therapeutics price target raised to $94 from $92 at Morgan Stanley
- PTC Therapeutics upgraded to Buy from Hold at TD Cowen
- PTC Therapeutics reports Q1 EPS (3c) vs. ($10.04) last year